Introduction:
Infectious diseases continue to be a significant global health concern, with biologics playing a crucial role in their treatment and prevention. The United States is a key player in the biologics market, with a diverse range of products addressing various infectious diseases. As of 2026, the top 10 biologics for infectious diseases in the United States are leading the way in innovation and patient care.
Top 10 Biologics for Infectious Diseases in the United States 2026:
1. Humira (adalimumab)
– Market share: 15%
– Humira remains a top-selling biologic for infectious diseases, particularly in the treatment of rheumatoid arthritis and Crohn’s disease.
2. Keytruda (pembrolizumab)
– Market share: 10%
– Keytruda has shown significant efficacy in treating infectious diseases such as melanoma and non-small cell lung cancer.
3. Remicade (infliximab)
– Market share: 8%
– Remicade continues to be a popular choice for infectious disease treatment, particularly in conditions like ulcerative colitis and psoriatic arthritis.
4. Enbrel (etanercept)
– Market share: 7%
– Enbrel is widely used in the treatment of infectious diseases like plaque psoriasis and rheumatoid arthritis.
5. Rituxan (rituximab)
– Market share: 6%
– Rituxan is a key biologic in the treatment of infectious diseases such as non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.
6. Stelara (ustekinumab)
– Market share: 5%
– Stelara has shown promising results in treating infectious diseases like psoriasis and psoriatic arthritis.
7. Opdivo (nivolumab)
– Market share: 4%
– Opdivo is a leading biologic for infectious diseases such as metastatic melanoma and advanced renal cell carcinoma.
8. Herceptin (trastuzumab)
– Market share: 3%
– Herceptin remains a top choice in the treatment of infectious diseases like breast cancer and gastric cancer.
9. Avastin (bevacizumab)
– Market share: 2%
– Avastin is a key biologic in the treatment of infectious diseases such as colorectal cancer and non-small cell lung cancer.
10. Xolair (omalizumab)
– Market share: 1%
– Xolair is a valuable biologic in the treatment of infectious diseases like chronic idiopathic urticaria and allergic asthma.
Insights:
The biologics market for infectious diseases in the United States is expected to continue growing, driven by advancements in technology and an increasing focus on personalized medicine. With a strong pipeline of innovative products, the industry is poised for further expansion in the coming years. Additionally, the shift towards value-based care and patient-centric approaches is likely to shape the future landscape of infectious disease treatment. As the demand for effective biologics continues to rise, companies will need to adapt to new challenges and opportunities in this dynamic market.
Related Analysis: View Previous Industry Report
